Does cardiac AAV6-betaARKct gene therapy improve cardiac function and remodeling in chronic heart failure?
AAV6-betaARKct gene therapy improves cardiac function and reverses remodeling in chronic heart failure, showing potential long-term therapeutic value.
Long-term cardiac AAV6-betaARKct gene therapy in HF results in sustained improvement of global cardiac function and reversal of remodeling at least in part as a result of a normalization of the neurohormonal signaling axis. In addition, betaARKct alone improves outcomes more than a beta-blocker alone, whereas both treatments are compatible. These findings show that betaARKct gene therapy can be of long-term therapeutic value in HF.
Rengo et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: